<?xml version="1.0" encoding="UTF-8"?>
<p>Chikungunya in humans was studied in 1159/2326 (50%) articles: 1040 observational and 49 experimental studies. The experimental studies comprised 3/49 (6%) challenge trials for potential vaccine candidates. Of the controlled trials (17/49; 35%), four studied vaccination in humans. All vaccination studies were at the experimental or trial stages. The efficacy of drugs to treat chikungunya symptoms was assessed in 3/17 (18%) controlled trial studies in humans. Other controlled trials included 
 <italic>in vitro</italic> studies using human blood cells from volunteers to assess potential antiviral or vaccine candidates (11/17; 65%).
</p>
